Islay Capital Management LLC Buys 1,845 Shares of Cencora, Inc. $COR

Islay Capital Management LLC lifted its stake in shares of Cencora, Inc. (NYSE:COR) by 30.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,987 shares of the company’s stock after acquiring an additional 1,845 shares during the period. Cencora makes up about 1.6% of Islay Capital Management LLC’s investment portfolio, making the stock its 20th largest holding. Islay Capital Management LLC’s holdings in Cencora were worth $2,698,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently made changes to their positions in COR. Vanguard Group Inc. grew its position in Cencora by 0.9% in the fourth quarter. Vanguard Group Inc. now owns 23,617,117 shares of the company’s stock valued at $7,976,681,000 after purchasing an additional 221,570 shares in the last quarter. State Street Corp grew its position in Cencora by 1.3% in the fourth quarter. State Street Corp now owns 9,305,507 shares of the company’s stock valued at $3,142,935,000 after purchasing an additional 115,191 shares in the last quarter. Geode Capital Management LLC grew its position in Cencora by 3.2% in the fourth quarter. Geode Capital Management LLC now owns 5,459,476 shares of the company’s stock valued at $1,843,268,000 after purchasing an additional 169,055 shares in the last quarter. JPMorgan Chase & Co. grew its position in Cencora by 6.5% in the fourth quarter. JPMorgan Chase & Co. now owns 4,982,557 shares of the company’s stock valued at $1,682,859,000 after purchasing an additional 304,760 shares in the last quarter. Finally, Boston Partners grew its position in Cencora by 2.0% in the third quarter. Boston Partners now owns 4,509,165 shares of the company’s stock valued at $1,409,152,000 after purchasing an additional 89,506 shares in the last quarter. Institutional investors own 97.52% of the company’s stock.

Cencora Stock Performance

NYSE COR opened at $281.58 on Tuesday. The firm has a 50-day moving average of $288.36 and a 200-day moving average of $326.67. The company has a debt-to-equity ratio of 3.40, a quick ratio of 0.59 and a current ratio of 0.95. The stock has a market cap of $54.78 billion, a PE ratio of 21.59, a P/E/G ratio of 1.52 and a beta of 0.59. Cencora, Inc. has a 52-week low of $244.82 and a 52-week high of $377.54.

Cencora (NYSE:COR) last issued its quarterly earnings data on Wednesday, May 6th. The company reported $4.75 earnings per share for the quarter, missing the consensus estimate of $4.82 by ($0.07). Cencora had a return on equity of 135.20% and a net margin of 0.78%.The business had revenue of $78.36 billion during the quarter, compared to analyst estimates of $81.09 billion. During the same quarter last year, the firm earned $4.42 EPS. Cencora’s revenue for the quarter was up 3.9% compared to the same quarter last year. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. On average, sell-side analysts anticipate that Cencora, Inc. will post 17.79 EPS for the current year.

Cencora announced that its Board of Directors has authorized a stock repurchase program on Thursday, May 21st that allows the company to repurchase $2.00 billion in shares. This repurchase authorization allows the company to buy up to 3.9% of its stock through open market purchases. Stock repurchase programs are often a sign that the company’s leadership believes its shares are undervalued.

Cencora Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, June 1st. Shareholders of record on Friday, May 15th were paid a $0.60 dividend. The ex-dividend date was Friday, May 15th. This represents a $2.40 annualized dividend and a yield of 0.9%. Cencora’s payout ratio is 18.40%.

Analysts Set New Price Targets

A number of research analysts recently weighed in on COR shares. William Blair started coverage on shares of Cencora in a research report on Tuesday, April 28th. They issued a “market perform” rating for the company. Barclays decreased their target price on shares of Cencora from $425.00 to $350.00 and set an “overweight” rating for the company in a research report on Wednesday, June 10th. Morgan Stanley set a $342.00 target price on shares of Cencora in a research report on Friday, May 8th. Citigroup decreased their target price on shares of Cencora from $405.00 to $355.00 and set a “buy” rating for the company in a research report on Thursday, May 7th. Finally, Evercore set a $360.00 target price on shares of Cencora in a research report on Wednesday, April 8th. Twelve equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $374.00.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.